Orphan Drugs and Rare Diseases: Slovakia
The legal framework for regulatory reform in Slovakian Pharma. Prepared in association with PRK Partners, a leading global law firm, this is an…
Tagged with Pharma
Biosimilars and Biologics: Slovakia
The legal framework for regulatory reform in Slovakian Pharma. Prepared in association with PRK Partners, a leading global law firm, this is an…
Localization: Slovakia
The legal framework for regulatory reform in Slovakian Pharma. Prepared in association with PRK Partners, a leading global law firm, this is an…
Russia Pharma News: Biocad Ramps up Sputnik V Manufacturing;…
The latest news from Russian pharma, including Biocad’s ramping up of Sputnik V COVID-19 vaccine manufacturing, Geropharm’s deal to produce…
Ichnos CEO on Glenmark Legacy, Biotech Transformation &…
After an illustrious career in oncology R&D, contributing greatly to the development of cutting-edge cancer therapies at Novartis and Gilead,…
Jazz’s $7.2 Billion GW Pharma Deal: A Major Boost for…
The first day of March 2013 also marked a first for GW Pharmaceuticals. On that day, the British biopharmaceutical company successfully listed on…
Swiss Pharma: Staying the Course
This article forms part of Healthcare & Life Sciences Review: Switzerland February 2021, a comprehensive up-to-date country report on the Swiss…
Top Turkish Biopharma Companies 2020
As Turkey's pharmaceutical industry makes its first steps away from competitive low-value generics towards biopharmaceuticals, a number of domestic…
Europe: EMA Medicine Approvals 2020
The full list of medicines recommended for approval by the European Medicines Agency (EMA) in 2020 divided by therapeutic area and with drugs that…
Japan PMDA New Drug Approvals 2020
Following on from our recent compilations of 2020 new drug approvals in the USA, China, and Switzerland, see below for the Japanese PMDA's new drug…
China: AstraZeneca/Junshi anti-PD-1 Tie-Up; New UK Biologics Plan…
The latest from Chinese pharma, including a new deal between AstraZeneca and Junshi Biosciences; Innoforce and dMed’s R&D collab; and investment…
ISREC’s Susan Gasser: A “Hard-Nosed” Approach to Research…
After 15 years as director at the Friedrich Miescher Institute for Biomedical Research (FMI) (2004-2019) and even longer as the group leader at her…
Page: 1 |
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197